Jasper Ridge Partners’s Aimmune Therapeutics AIMT Stock Holding History

Jasper Ridge Partners’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,385	Closed	-$358K	–	118
2020 Q3	$358K	Hold	10,385	–	–	0.02%	102
2020 Q2	$174K	Hold	10,385	–	–	0.01%	102
2020 Q1	$150K	Hold	10,385	–	–	0.01%	95
2019 Q4	$348K	Hold	10,385	–	–	0.02%	85
2019 Q3	$217K	Hold	10,385	–	–	0.01%	89
2019 Q2	$216K	Hold	10,385	–	–	0.01%	91
2019 Q1	$232K	Hold	10,385	–	–	0.01%	81
2018 Q4	$248K	Hold	10,385	–	–	0.02%	67
2018 Q3	$283K	Hold	10,385	–	–	0.02%	68
2018 Q2	$279K	Hold	10,385	–	–	0.02%	62
2018 Q1	$331K	Hold	10,385	–	–	0.02%	54
2017 Q4	$393K	Buy	+10,385	New	+$335K	0.03%	51

Jasper Ridge Partners's AIMT Position: Q4 2020 in Review

Jasper Ridge Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 10,385 shares — an estimated $358K sold.

Jasper Ridge Partners first reported a position in AIMT in Q4 2017 and held it in 12 quarters. The position peaked at $393K in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Jasper Ridge Partners reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Jasper Ridge Partners sold 10,385 Aimmune Therapeutics shares in Q4 2020, an estimated $358K.
Jasper Ridge Partners first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 12 quarters.
Jasper Ridge Partners's Aimmune Therapeutics position peaked at $393K in Q4 2017.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Jasper Ridge Partners's 13F filing for Q4 2020, filed 12 Feb 2021.